Association of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists

J Intern Med. 2023 Jan;293(1):124-127. doi: 10.1111/joim.13569. Epub 2022 Sep 20.

Authors

D Max van Heteren^{1

2}, Willem M Lijfering³, Felix J M van der Meer¹, Pieter H Reitsma^{1

4}, Jesse J Swen⁴, Mettine H A Bos^{1

4}, Nienke van Rein^{1

2

3

4}

Affiliations

¹ Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.
² Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
³ Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
⁴ Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anticoagulants* / adverse effects
Hemorrhage / chemically induced
Hemorrhage / genetics
Humans
Polymorphism, Genetic
Vitamin K Epoxide Reductases / genetics
Vitamin K*

Substances

Anticoagulants
Vitamin K
VKORC1 protein, human
Vitamin K Epoxide Reductases